Cetuximab inhibits oral squamous cell carcinoma invasion and metastasis via degradation of epidermal growth factor receptor

Journal of Oral Pathology and Medicine

Volumn 43, Issue 4, 2014, Pages 250-257

  Dai, Wei ^a   Li, Yanshu ^a   Zhou, Qing ^a   Xu, Zhongfei ^a   Sun, Changfu ^a   Tan, Xuexin ^a   Lu, Li ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Cetuximab; Epidermal growth factor receptor; Immunoprecipitation; Tongue cancer

Indexed keywords

BETA5 INTEGRIN; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; F ACTIN; PROTEASOME; PROTEIN KINASE B; UBIQUITIN; UVOMORULIN; VIMENTIN; ACTIN; BENZYLOXYCARBONYLLEUCYL-LEUCYL-LEUCINE ALDEHYDE; BETA INTEGRIN; CYSTEINE PROTEINASE INHIBITOR; LEUPEPTIN; MONOCLONAL ANTIBODY; ONCOPROTEIN;

ACTIN FILAMENT; ANCHORAGE INDEPENDENT GROWTH; ARTICLE; CELL ADHESION; CELL INVASION; CELL LYSATE; CELL MIGRATION; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; METASTASIS; MOUTH SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN STABILITY; STEADY STATE; TONGUE CARCINOMA; TUMOR INVASION; UBIQUITINATION; WOUND HEALING; ANTAGONISTS AND INHIBITORS; CELL MOTION; CELL PROLIFERATION; CULTURE TECHNIQUE; DRUG EFFECTS; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PROTEIN PROCESSING; SECONDARY; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; TONGUE TUMOR; TOXICITY; TUMOR CELL LINE;

ACTINS; ANTIBODIES, MONOCLONAL, HUMANIZED; CARCINOMA, SQUAMOUS CELL; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CYSTEINE PROTEINASE INHIBITORS; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; INTEGRIN BETA CHAINS; LEUPEPTINS; MAP KINASE SIGNALING SYSTEM; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; ONCOGENE PROTEIN V-AKT; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTOR, EPIDERMAL GROWTH FACTOR; TONGUE NEOPLASMS; UBIQUITIN;

EID: 84898057299     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/jop.12116     Document Type: Article

References (34)

1. Wali RK, Kunte DP, De La Cruz M, et al. Topical polyethylene glycol as a novel chemopreventive agent for oral cancer via targeting of epidermal growth factor response. PLoS ONE 2012; 7: e38047.
2. Moskowitz HS, Gooding WE, Thomas SM, et al. Serum biomarker modulation following molecular targeting of epidermal growth factor and cyclooxygenase pathways: a pilot randomized trial in head and neck cancer. Oral Oncol 2012; 48: 1136-45.
3. Reynolds AR, Tischer C, Verveer PJ, et al. EGFR activation coupled to inhibition of tyrosine phosphatases causes lateral signal propagation. Nat Cell Biol 2003; 5: 447-53.
4. Arteaga CL. Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist 2002; 7: 31-9.
5. Prenzel N, Fischer OM, Streit S, et al. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer 2001; 8: 11-31.
6. Olayioye MA, Neve RM, Lane HA, et al. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000; 19: 3159-67.
7. Lu Z, Jiang G, Blume-Jensen P, et al. Epidermal growth factor-induced tumor cell invasion and metastasis initiated by dephosphorylation and downregulation of focal adhesion kinase. Mol Cell Biol 2001; 21: 4016-31.
8. Sartor CI. Biological modifiers as potential radiosensitizers: targeting the epidermal growth factor receptor family. Semin Oncol 2000; 27: 15-20.
9. Newby JC, Johnston SR, Smith IE, et al. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer. Clin Cancer Res 1997; 3: 1643-51.
10. Chen X, Yeung TK, Wang Z. Enhanced drug resistance in cells coexpressing ErbB2 with EGF receptor or ErbB3. Biochem Biophys Res Commun 2000; 277: 757-63.
11. Magné N, Pivot X, Bensadoun RJ, et al. The relationship of epidermal growth factor receptor levels to the prognosis of unresectable pharyngeal cancer patients treated by chemo-radiotherapy. Eur J Cancer 2001; 37: 2169-77.
12. Fischer-Colbrie J, Witt A, Heinzl H, et al. EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients. Anticancer Res 1997; 17: 613-9.
13. Luedke E, Jaime-Ramirez AC, Bhave N, et al. Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines. Surgery 2012; 152: 431-40.
14. Kneissl J, Keller S, Lorber T, et al. Association of amphiregulin with the cetuximab sensitivity of gastric cancer cell lines. Int J Oncol 2012; 41: 733-44.
15. Maurizi M, Almadori G, Ferrandina G, et al. Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma. Br J Cancer 1996; 74: 1253-7.
16. Herbst RS, Kim ES, Harari PM. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer. Expert Opin Biol Ther 2001; 1: 719-32.
17. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010; 11: 21-8.
18. Rangaraju RR, Sharma JB, Dewan AK, et al. Palliative weekly chemotherapy along with cetuximab in recurrent and metastatic head and neck cancers: a retrospective analysis. Indian J Cancer 2012; 49: 1-5.
19. Péron J, Ceruse P, Lavergne E, et al. Paclitaxel and cetuximab combination efficiency after the failure of a platinum-based chemotherapy in recurrent/metastatic head and neck squamous cell carcinoma. Anticancer Drugs 2012; 23: 996-1001.
20. Ciardiello F, Bianco R, Damiano V, et al. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res 1999; 5: 909-16.
21. Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 1999; 59: 1935-40.
22. Buchsbaum DJ, Bonner JA, Grizzle WE, et al. Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation. Int J Radiat Oncol Biol Phys 2002; 54: 1180-93.
23. Uberall I, Krizova K, Steigerova J. Cetuximab enhances the anti-proliferative effect of trastuzumab in ERBB2 over-expressing breast cancer cells-preliminary study. Klin Onkol 2011; 24: 356-60.
24. Shin DM, Donato NJ, Perez-Soler R, et al. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin Cancer Res 2001; 7: 1204-13.
25. Leifheit-Nestler M, Conrad G, Heida NM, et al. Overexpression of integrin beta 5 enhances the paracrine properties of circulating angiogenic cells via Src kinase-mediated activation of STAT3. Arterioscler Thromb Vasc Biol 2010; 30: 1398-406.
26. Aquino G, Pannone G, Santoro A, et al. pEGFR-Tyr 845 expression as prognostic factors in oral squamous cell carcinoma: a tissue-microarray study with clinic-pathological correlations. Cancer Biol Ther 2012; 13: 967-77.
27. Nakata Y, Uzawa N, Takahashi K, et al. EGFR gene copy number alteration is a better prognostic indicator than protein overexpression in oral tongue squamous cell carcinomas. Eur J Cancer 2011; 47: 2364-72.
28. Wu Z, Doondeea JB, Gholami AM, et al. Quantitative chemical proteomics reveals new potential drug targets in head and neck cancer. Mol Cell Proteomics 2011; 10: M111.011635.
29. Wei X. Mechanism of EGER-related cancer drug resistance. Anticancer Drugs 2011; 22: 963-70.
30. Liska D, Chen CT, Bachleitner-Hofmann T, et al. HGF rescues colorectal cancer cells from EGFR inhibition via MET activation. Clin Cancer Res 2011; 17: 472-82.
31. Sano D, Choi S, Milas ZL, et al. The effect of combination anti-endothelial growth factor receptor and anti-vascular endothelial growth factor receptor 2 targeted therapy on lymph node metastasis: a study in an orthotopic nude mouse model of squamous cell carcinoma of the oral tongue. Arch Otolaryngol Head Neck Surg 2009; 135: 411-20.
32. Barnes CJ, Ohshiro K, Rayala SK, et al. Insulin-like growth factor receptor as a therapeutic target in head and neck cancer. Clin Cancer Res 2007; 13: 4291-9.
33. Misra A, Pandey C, Sze SK, et al. Hypoxia Activated EGFR Signaling Induces Epithelial to Mesenchymal Transition (EMT). PLoS ONE 2012; 7: e49766.
34. Ayuso-Sacido A, Moliterno JA, Kratovac S, et al. Activated EGFR signaling increases proliferation, survival, and migration and blocks neuronal differentiation in post-natal neural stem cells. J Neurooncol 2010; 97: 323-37.